Examples of 'macitentan' in a sentence
Meaning of "macitentan"
macitentan (noun) - refers to a drug or medication used for a specific medical purpose, often related to healthcare or pharmaceuticals
Show more definitions
- An endothelin receptor antagonist used to treat pulmonary arterial hypertension.
How to use "macitentan" in a sentence
Basic
Advanced
macitentan
Macitentan is excreted only after extensive metabolism.
It is unknown whether macitentan is excreted in human milk.
Macitentan has four primary metabolic pathways.
Opsumit contains the active substance macitentan.
Macitentan had a low order of acute toxicity in rodents.
Dual ERAs include bosentan and macitentan.
Macitentan and its active metabolite.
There are no data on the use of macitentan in pregnant women.
Pharmaceutical composition containing crystalline macitentan.
Macitentan was not phototoxic in vivo.
The active substance is macitentan.
Macitentan was teratogenic in rabbits and rats at all doses tested.
Opsumit is a medicine that contains the active substance macitentan.
There are no data from the use of macitentan in pregnant women.
Preparation of pyrimidine intermediates useful for the manufacture of macitentan.
See also
Macitentan was teratogenic in rabbits and rats at all dose levels tested.
Therapeutic compositions containing macitentan.
It is not known whether macitentan is excreted into human breast milk.
Macitentan was not genotoxic in a standard battery of in vitro and in vivo assays.
Hypotension has been associated with the use of ERAs including macitentan.
Macitentan for use in the prevention or treatment of brain metastases in combination.
The safety and efficacy of macitentan in children have not yet been established.
Macitentan primarily undergoes oxidative depropylation of the sulfamide to form a pharmacologically active metabolite.
Adverse reactions associated with macitentan obtained from this clinical study are tabulated below.
Cases of anaemia requiring blood cell transfusion have been reported with macitentan and other ERAs.
The pharmacokinetics of macitentan and its active metabolite were not affected by warfarin.
Oedema / fluid retention has been associated with the use of ERAs including macitentan.
The pharmacokinetics of macitentan and its active metabolite have mainly been documented in healthy subjects.
At clinically relevant concentrations, the active metabolite of macitentan is not an inhibitor of P-gp.
Treatment with macitentan also caused a reduction in the numbers of implantation sites and live embryos.
In the presence of strong CYP3A4 inducers reduced efficacy of macitentan could occur.
Maximum plasma concentrations of macitentan are achieved about 8 hours after administration.
Macitentan inhibits the breast cancer resistance protein ( BCRP ) at clinically relevant intestinal concentrations.
Physicochemical properties, Macitentan is a crystalline powder that is insoluble in water.
The pharmacodynamic effect of warfarin on International Normalized Ratio ( INR ) was not affected by macitentan.
In rats, macitentan and its metabolites were excreted into milk during lactation.
The pharmacodynamic effect of warfarin on International Normalised Ratio ( INR ) was not affected by macitentan.
In dogs, macitentan decreased blood pressure at exposures similar to the therapeutic human exposure.
The increase in 6MWD achieved with macitentan was maintained for the duration of the study.
Macitentan has been administered as a single dose of up to 600 mg to healthy subjects.
Exposure to the active metabolite of macitentan was reduced by 26.
The effect of macitentan on human male fertility is not known section 4.6.
After repeated administration of doses of ≤ 30 mg, the pharmacokinetics of macitentan are dose proportional.
In rats, macitentan and its metabolites are excreted into milk during lactation see section 5.3.
After repeated administration, the pharmacokinetics of macitentan are dose-proportional up to and including 30 mg.
In a particularly preferred embodiment, the dual endothelin receptor antagonist of embodiment 19 will be macitentan.
Steady-state conditions of macitentan and its active metabolite are achieved after 3 days and 7 days, respectively.
Said compound of formula I-2 or its salt can be used to prepare macitentan.
Exposure to macitentan in patients with PAH was approximately 1.2-fold greater than in healthy subjects.
Each film-coated tablet contains 10 mg macitentan.
